Ann: Medgate extends European ResAppDx trial, page-33

Totally agree, this is further clinical validation (after Ilara Health and Morayfield use in clinic) where ResAppDx-EU has been commercially used by one of the largest telehealth provider in Europe where they will look at CE Mark regulatory approval (as they should given ResAppDx-EU was extensively review for 6 months for safety and efficacy). Another massive market will be screening of chronic management of Asthma and COPD attacks so the patient will know the correct dosage of medication to take when they are really having an attack instead of subjectively guessing which will save government and business a lot of money from unnecessary hospitalisation due to medication overdose.

https://triagelogic.com/insurance-reimbursements-for-remote-patient-monitoring/